U.S. court blocks mail-order access to abortion drugs, limiting distribution of mifepristone; a setback for reproductive rights advocates.

The Headline

Court blocks mail-order mifepristone access

Key Facts

A federal appeals court on Friday temporarily blocked a federal rule allowing the abortion drug mifepristone to be dispensed through the mail, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion.
The 5th Circuit U.S. Court of Appeals ruling is seen as a significant win for the anti-abortion movement, which has sought to reinstate in-person dispensing requirements.
Reproductive rights advocates have voiced concerns that the ruling will limit access to necessary abortion care across the country.
Gov. Gretchen Whitmer criticized the ruling as 'another dangerous, partisan attempt to erode reproductive freedom.'
An emergency appeal to the Supreme Court is anticipated, according to the Guttmacher Institute.

Background Context

Key Facts

Louisiana's Republican Attorney General hailed the court ruling, stating that she looks forward to defending women and babies as the case continues.
Studies cited by the Biden administration indicate that major adverse events related to mifepristone occur in fewer than 1% of patients, emphasizing its effectiveness and safety.
Louisiana sued the FDA last year, arguing that the agency ignored risks associated with mifepristone when adopting the 2023 rule.